David J. Augeri

5.5k citations

21 papers · 870 indexed · h-index 12

Computational Theory and Mathematics top 5%
Molecular Biology
- Protein Kinase Regulation and GTPase Signaling 2
- Retinoids in leukemia and cellular processes 2
- RNA Research and Splicing 2
Oncology
- Cancer-related Molecular Pathways 2
Organic Chemistry top 10%
- Synthesis and Catalytic Reactions 2
Cancer Research
- Cancer, Hypoxia, and Metabolism 3
- Protease and Inhibitor Mechanisms 2
Nutrition and Dietetics
- Trace Elements in Health 3

Co-authors: Philip J. Hajduk Stephen W. Fesik Jianguo Yang J. Mack Stephen F. Betz Renaldo Mendoza S. David Kimball Andrew M. Petros
Cited by: Computational Theory and Mathematics Molecular Biology Oncology
Journals: Journal of the American Chemical Society (1 paper)Blood (2 papers)Oncogene (1 paper)
Partner nations: United States Italy Canada

In The Last Decade

David J. Augeri

20 papers receiving 844 citations

Peers

Countries citing papers authored by David J. Augeri

Since Specialization

Citations

This map shows the geographic impact of David J. Augeri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David J. Augeri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David J. Augeri more than expected).

Fields of papers citing papers by David J. Augeri

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David J. Augeri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David J. Augeri. The network helps show where David J. Augeri may publish in the future.

Co-authorship network

The 25 scholars most cited alongside David J. Augeri, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David J. Augeri Line = papers co-authored together David J. Augeri links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Structure–Activity Relationship of a Pyrrole Based Series of PfPKG Inhibitors as Anti-Malarials Journal of Medicinal Chemistry ·John Gilleran,Kutub Ashraf,Melvin Delvillar,Tyler Eck,Raheel Fondekar,Edward B. Miller,Ashley Hutchinson,Aiping Dong,Alma Seitova,Mariana Laureano de Souza,David J. Augeri,Levon Halabelian,John J. Siekierka,David P. Rotella,John Gordon,Wayne E. Childers,Mark C. Grier,Bart L. Staker,Jacques Y. Roberge,Purnima Bhanot	2024	3
2	A novel and highly effective mitochondrial uncoupling drug in T-cell leukemia Blood ·Victoria da Silva-Diz,Bin Cao,Olga Lancho,Eric Chiles,Amer Alasadi,Maya Aleksandrova,Shirley Luo,Amartya Singh,Hanlin Tao,David J. Augeri,Sonia Minuzzo,Stefano Indraccolo,Hossein Khiabanian,Xiaoyang Su,Shengkan Jin,Daniel Herranz	2021	8
3	Synthesis and Structural Characterization of Ricin Inhibitors Targeting Ribosome Binding Using Fragment-Based Methods and Structure-Based Design Journal of Medicinal Chemistry ·Xiaoping Li,Rajesh K. Harijan,Bin Cao,Jennifer Nielsen Kahn,Michael Pierce,Anastasiia M. Tsymbal,Jacques Y. Roberge,David J. Augeri,Nilgun E. Tumer	2021	8
4	Mitochondrial uncoupler MB1-47 is efficacious in treating hepatic metastasis of pancreatic cancer in murine tumor transplantation models Oncogene ·Amer Alasadi,Bin Cao,Jingjing Guo,Hanlin Tao,Juan Carlos Collantes,Victor M. Tan,Xiaoyang Su,David J. Augeri,Shengkan Jin	2021	7
5	Benzothiazolyl and Benzoxazolyl Hydrazones Function as Zinc Metallochaperones to Reactivate Mutant p53 Journal of Medicinal Chemistry ·John Gilleran,Xin Yu,Alan J. Blayney,Anthony F. Bencivenga,Bing Na,David J. Augeri,Adam R. Blanden,S. David Kimball,Stewart N. Loh,Jacques Y. Roberge,Darren R. Carpizo	2021	24
6	Targeting bone morphogenetic protein receptor 2 sensitizes lung cancer cells to TRAIL by increasing cytosolic Smac/DIABLO and the downregulation of X-linked inhibitor of apoptosis protein Cell Communication and Signaling ·Rachel NeMoyer,Arindam Mondal,Mehul Vora,Elaine Langenfeld,Danea Glover,Michael J. Scott,Lauren Lairson,Christopher Rongo,David J. Augeri,Youyi Peng,Salma K. Jabbour,John Langenfeld	2019	6
7	Synthesis and Characterization of Novel BMI1 Inhibitors Targeting Cellular Self-Renewal in Hepatocellular Carcinoma Targeted Oncology ·Monica Bartucci,Mohamed S. Hussein,Eric Huselid,Kathleen Flaherty,Michele Patrizii,Saurabh V. Laddha,Cindy Kui,Rachel A. Bigos,John Gilleran,Mervat Mohamed S. El Ansary,Mona A.M. Awad,S. David Kimball,David J. Augeri,Hatem E. Sabaawy	2017	19
8	Synthetic Metallochaperone ZMC1 Rescues Mutant p53 Conformation by Transporting Zinc into Cells as an Ionophore Molecular Pharmacology ·Adam R. Blanden,Xin Yu,Aaron J. Wolfe,John Gilleran,David J. Augeri,Ryan S. O’Dell,Eric C. Olson,S. David Kimball,Thomas J. Emge,Liviu Movileanu,Darren R. Carpizo,Stewart N. Loh	2015	69
9	Small molecule restoration of wildtype structure and function of mutant p53 using a novel zinc-metallochaperone based mechanism Oncotarget ·Xin Yu,Adam R. Blanden,Sumana Narayanan,Lalithapriya Jayakumar,David Lubin,David J. Augeri,S. David Kimball,Stewart N. Loh,Darren R. Carpizo	2014	82
10	OP0195 Genetic and Pharmacologic Inhibition of MST1 Blocks Lymphocyte Function and Protects Against Inflammation and Autoimmunity Annals of the Rheumatic Diseases ·Tamás Oravecz,Wei-Chun Chang,Kanchan G. Jhaver,Amin Al-Shami,Theodore C. Jessop,Brian D. Hamman,Jeffrey T. Bagdanoff,David J. Augeri,Peter Vogel,Jonathan C. Swaffield,Alan Wilson,Kenneth G. Carson,Alan J. Main,Brian Zambrowicz	2013	0
11	Discovery of a Potent Inhibitor of the Antiapoptotic Protein Bcl-x _L from NMR and Parallel Synthesis Journal of Medicinal Chemistry ·Andrew M. Petros,Jürgen Dinges,David J. Augeri,Steven A. Baumeister,David A. Betebenner,Mark G. Bures,Steven W. Elmore,Philip J. Hajduk,Mary K. Joseph,Shelley K. Landis,David G. Nettesheim,Saul H. Rosenberg,Shen Wang,Sheela A. Thomas,Xilu Wang,Irini Zanze,Haichao Zhang,Stephen W. Fesik	2005	229
12	NMR-Based Modification of Matrix Metalloproteinase Inhibitors with Improved Bioavailability Journal of Medicinal Chemistry ·Philip J. Hajduk,Suzanne B. Shuker,David G. Nettesheim,R.G. Craig,David J. Augeri,David A. Betebenner,Daniel H. Albert,Yan Guo,Robert Meadows,Lianhong Xu,Michael R. Michaelides,Steven K. Davidsen,Stephen W. Fesik	2002	49
13	NMR-Based Screening of Proteins Containing ¹³C-Labeled Methyl Groups Journal of the American Chemical Society ·Philip J. Hajduk,David J. Augeri,J. Mack,Renaldo Mendoza,Jianguo Yang,Stephen F. Betz,Stephen W. Fesik	2000	166
14	Potent and orally bioavailable noncysteine-containing inhibitors of protein farnesyltransferase Bioorganic & Medicinal Chemistry Letters ·David J. Augeri,Dave Janowick,Douglas Kalvin,Gerry Sullivan,John J. Larsen,Daniel A. Dickman,Hong Ding,Jerry D. Cohen,Jang Lee,Robert B. Warner,Peter Kovar,Sajeev Cherian,Badr Saeed,Haichao Zhang,Steve Tahir,Shi-Chung Ng,Hing L. Sham,Saul H. Rosenberg	1999	28
15	Novel Inhibitors of Erm Methyltransferases from NMR and Parallel Synthesis Journal of Medicinal Chemistry ·Philip J. Hajduk,Jürgen Dinges,Jeffrey M. Schkeryantz,David A. Janowick,Michele Kaminski,Michael D. Tufano,David J. Augeri,Andrew M. Petros,V. Nienaber,Ping Zhong,Rachel Hammond,Michael Coen,Bruce A. Beutel,Leonard Katz,Stephen W. Fesik	1999	80
16	Potent and Selective Non-Cysteine-Containing Inhibitors of Protein Farnesyltransferase Journal of Medicinal Chemistry ·David J. Augeri,Stephen J. O’Connor,Dave Janowick,Bruce G. Szczepankiewicz,Gerry Sullivan,John J. Larsen,Douglas Kalvin,Jerry D. Cohen,Edward M. Devine,Haichao Zhang,Sajeev Cherian,Badr Saeed,Shi‐Chung Ng,Saul H. Rosenberg	1998	38
17	N-Aminoaziridinylhydrazones: Highly diastereoselective alkylation without chelation, and a syn-directing effect Tetrahedron Letters ·David J. Augeri,A. Richard Chamberlin	1994	3
18	Novel [3+2] and [3+3] 4-quinolone annulations by tandem Claisen-Cope amidoalkylation reaction The Journal of Organic Chemistry ·Bradley J. Newhouse,Jon Bordner,David J. Augeri,Christopher Litts,Edward F. Kleinman	1992	27
19	Synthesis and antibacterial activity of 2,3‐dehydroofloxacin Journal of Heterocyclic Chemistry ·David J. Augeri,Andrew H. Fray,Edward F. Kleinman	1990	4
20	A convenient synthesis of 3,6-disubstituted 3,6-diazabicyclo[3.2.2]nonanes and 3,6-diazabicyclo[3.2.1]octanes The Journal of Organic Chemistry ·Andrew H. Fray,David J. Augeri,Edward F. Kleinman	1988	17

About David J. Augeri

David J. Augeri is a scholar working on Cancer Research, Toxicology and Oncology, having authored 21 papers that have together received 870 indexed citations. Recurring topics across this work include Cancer, Hypoxia, and Metabolism (3 papers), Trace Elements in Health (3 papers), Synthesis and Catalytic Reactions (2 papers), Protein Kinase Regulation and GTPase Signaling (2 papers), Retinoids in leukemia and cellular processes (2 papers), Protease and Inhibitor Mechanisms (2 papers), Cancer-related Molecular Pathways (2 papers) and RNA Research and Splicing (2 papers). The work is most often cited by research in Computational Theory and Mathematics (156 citations), Molecular Biology (635 citations) and Oncology (211 citations). David J. Augeri has collaborated with scholars based in United States, Italy and Canada. Frequent co-authors include Philip J. Hajduk, Stephen W. Fesik, Jianguo Yang, J. Mack, Stephen F. Betz, Renaldo Mendoza, S. David Kimball, Andrew M. Petros, Jürgen Dinges and Stewart N. Loh. Their work appears in journals such as Journal of the American Chemical Society, Blood and Oncogene.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact